Figure 3. Summary of survival analyses in patients with ALS from London and Oxford cohorts separately and combined.

(A) Distinct curves representing cumulative survivals in patients with ALS with different baseline plasma NfL and serum NfL levels in the London cohort (A.a), Oxford cohort (A.b), and combined cohort (A.c). All 3 cohorts were divided by cohort-specific tertile cutoff values. (B) Kaplan–Meier curve of patients with ALS treated with riluzole or untreated in the London cohort (B.a), Oxford cohort (B.b), and combined cohort (B.c).